US OptionsDetailed Quotes
DMAC250516C2500
- 0.00
- 0.000.00%
15min DelayClose May 2 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover904.67%IV-40.90%PremiumMay 16, 2025Expiry Date1.73Intrinsic Value100Multiplier12DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8752Delta0.0291Gamma1.43Leverage Ratio-0.0603Theta0.0003Rho1.25Eff Leverage0.0016Vega
DiaMedica Therapeutics Stock Discussion
DiaMedica's Dual Clinical Programs Show Progress as Cash Runway Extends to 2026
Revolutionary Stroke Treatment Mechanism Revealed: How DM199 Could Transform Patient Care
4 MINUTES AGO, 8:15 AM EST
VIA BUSINESSWIRE
Scientific insight into DM199's mechanism for increasing collateral circulation and salvaging brain tissue at-risk from infarction
DiaMedica Therapeutics Announces Publication of DM199's Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke
Thursday, 20th February at 8:15 am
Scientific insight into DM199's mechanism for increasing collateral circulation and salvaging brain tissue at-risk from infarction
DiaMedica Therapeutics Inc. (NASDAQ: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic dis...
2 MINUTES AGO, 8:27 AM EDT
VIA BUSINESSWIRE
• Dosing first participant expected in the fourth quarter of 2024 with preliminary proof-of-concept results targeted for the first half of 2025
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
• Dosing first participant expected in the fourth quarter of 2024 with preliminary proof-of-concept results targeted for the first half of 2025
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced regulatory approval has been...
DiaMedica Therapeutics Announces $11.8 Million Private Placement
NEWS
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
No comment yet